Spotlight on Nephrology

Credits: 1.00 CME / CNE / CPE
Advances in the Management of Acute and Chronic Hyperkalemia
Charles V. Pollack Jr., MA, MD, FACEP, FAHA, FACC, FESC
AcademicCME

Advances in the Management of Acute and Chronic Hyperkalemia

Start

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: October 20, 2020
Expires: October 19, 2021
60 minutes to complete

Accredited By

Target Audience

Community and community hospital-based generalist and specialist physicians, nurses, and pharmacists who manage patients with hyperkalemia.

Learning Objectives

  • Assess for hyperkalemia risk in patients with underlying diseases like heart failure, diabetes, or chronic kidney disease
  • Understand and differentiate among therapies for temporizing, acute, and chronic therapy for hyperkalemia
  • Analyze the latest evidence-based data for hyperkalemia therapeutics to inform clinical decision making in an era of advanced treatment of heart failure, diabetes, and chronic kidney disease

Activity Description

Hyperkalemia and its important cardiometabolic comorbidities are increasingly common, while the most frequently used acute therapy to lower potassium levels for over five decades is now recognized as being associated with serious adverse effects. Over the last four years, clinical trial data has identified newer and safer therapeutic options. The goals of better potassium management include facilitation of guidelines-recommended therapy for heart failure and hypertension, and support of the patient with chronic renal disease. In this unique program, we will discuss new and improved options for managing hyperkalemia acutely and chronically. This information will impact the practices of emergency medicine physicians, hospitalists, internists, cardiologists, nephrologists, and other clinicians.

Statement of Educational Need

Health care team members need to understand the most recent clinical trial data regarding the treatment of management of patients with hyperkalemia.

Agenda

  • Understand the Hyperkalemia Risk in Patients With Heart failure, Diabetes, or Chronic Kidney Disease
  • Acute and Temporizing Management of Hyperkalemia
  • Data Analysis and Interpretation: Applicability to Practice of Newer Potassium Binders

Faculty

Charles V. Pollack Jr., MA, MD, FACEP, FAHA, FACC, FESC
Clinician-Scientist
Department of Emergency Medicine
University of Mississippi School of Medicine
Jackson, Mississippi


Javed Butler, MD, MPH, MBA
Chairman and Professor
Department of Medicine
University of Mississippi Medical Center
Jackson, Mississippi


Disclosures of Conflict of Interest

It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:

Charles V. Pollack, Jr., MA, MD, FACEP, FAHA, FACC, FESC (Course Chair)
Relationship Identified With:
Grant/Research Support: AstraZeneca Pharmaceuticals; Boehringer-Ingelheim Pharmaceuticals; CSL Behring.

Javed Butler, MD, MPH, MBA
Relationship Identified With:
Consultant/Advisor: Amgen Inc.; Array; AstraZeneca Pharmaceuticals; Bayer AG; Boehringer Ingelheim; Bristol-Myers Squibb Company; CVRX Inc.; G3 Pharmaceuticals; Innolife; Janssen Scientific Affairs LLC.; Luitpold Pharmaceuticals, Inc.; Merck & Co.; Medtronics; Novartis Pharmaceuticals Corporation; Relypsa Inc.

Accreditation Statement

In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. This activity was planned by and for the healthcare team.

Designation of Credit

AcademicCME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™.

AcademicCME designates this enduring material for a maximum of 1.0 CNE Contact Hour (Provider Number P0491).

AcademicCME designates this continuing education activity for 1.0 CPE Contact Hour (0.10 CEU) of continuing pharmacy education credit (UAN #: JA4008190-0000-20-007-L04-P).

Participants should claim only the credit commensurate with the extent of their participation in the activity.

Method of Participation

In order to claim credit, participants must complete the following:

  • Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
  • Complete the Pre-Activity Questions.
  • Read or review the activity content.
  • Complete the Post-Activity Test Questions and Evaluation.
  • Learners who receive a grade of 66% or better on the Post-Activity Test Questions and complete the Evaluation will receive appropriate credit as indicated (CME, CNE, and/or CPE credit).
    CPE credit will be posted to the learner's CPE Monitor profile within 60 days of completion.
    CME and CNE credit will be issued appropriate certificate of completion.
    Others may request a "certificate of completion".
  • Learners should claim only the credit commensurate with the extent of their participation in the activity.

Statement of Commercial Support

This activity has been supported by an independent educational grant from AstraZeneca Pharmaceuticals.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and AstraZeneca Pharmaceuticals do not recommend the use of any agent outside of the labeled indications.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

For all CME/CE inquiries or special needs, please contact admin@academiccme.com or 610-687-3300.

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: October 20, 2020
Expires: October 19, 2021
60 minutes to complete

Accredited By

Target Audience

Community and community hospital-based generalist and specialist physicians, nurses, and pharmacists who manage patients with hyperkalemia.

Learning Objectives

  • Assess for hyperkalemia risk in patients with underlying diseases like heart failure, diabetes, or chronic kidney disease
  • Understand and differentiate among therapies for temporizing, acute, and chronic therapy for hyperkalemia
  • Analyze the latest evidence-based data for hyperkalemia therapeutics to inform clinical decision making in an era of advanced treatment of heart failure, diabetes, and chronic kidney disease

Activity Description

Hyperkalemia and its important cardiometabolic comorbidities are increasingly common, while the most frequently used acute therapy to lower potassium levels for over five decades is now recognized as being associated with serious adverse effects. Over the last four years, clinical trial data has identified newer and safer therapeutic options. The goals of better potassium management include facilitation of guidelines-recommended therapy for heart failure and hypertension, and support of the patient with chronic renal disease. In this unique program, we will discuss new and improved options for managing hyperkalemia acutely and chronically. This information will impact the practices of emergency medicine physicians, hospitalists, internists, cardiologists, nephrologists, and other clinicians.

Statement of Educational Need

Health care team members need to understand the most recent clinical trial data regarding the treatment of management of patients with hyperkalemia.

Agenda

  • Understand the Hyperkalemia Risk in Patients With Heart failure, Diabetes, or Chronic Kidney Disease
  • Acute and Temporizing Management of Hyperkalemia
  • Data Analysis and Interpretation: Applicability to Practice of Newer Potassium Binders

Faculty

Charles V. Pollack Jr., MA, MD, FACEP, FAHA, FACC, FESC
Clinician-Scientist
Department of Emergency Medicine
University of Mississippi School of Medicine
Jackson, Mississippi


Javed Butler, MD, MPH, MBA
Chairman and Professor
Department of Medicine
University of Mississippi Medical Center
Jackson, Mississippi


Disclosures of Conflict of Interest

It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:

Charles V. Pollack, Jr., MA, MD, FACEP, FAHA, FACC, FESC (Course Chair)
Relationship Identified With:
Grant/Research Support: AstraZeneca Pharmaceuticals; Boehringer-Ingelheim Pharmaceuticals; CSL Behring.

Javed Butler, MD, MPH, MBA
Relationship Identified With:
Consultant/Advisor: Amgen Inc.; Array; AstraZeneca Pharmaceuticals; Bayer AG; Boehringer Ingelheim; Bristol-Myers Squibb Company; CVRX Inc.; G3 Pharmaceuticals; Innolife; Janssen Scientific Affairs LLC.; Luitpold Pharmaceuticals, Inc.; Merck & Co.; Medtronics; Novartis Pharmaceuticals Corporation; Relypsa Inc.

Accreditation Statement

In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. This activity was planned by and for the healthcare team.

Designation of Credit

AcademicCME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™.

AcademicCME designates this enduring material for a maximum of 1.0 CNE Contact Hour (Provider Number P0491).

AcademicCME designates this continuing education activity for 1.0 CPE Contact Hour (0.10 CEU) of continuing pharmacy education credit (UAN #: JA4008190-0000-20-007-L04-P).

Participants should claim only the credit commensurate with the extent of their participation in the activity.

Method of Participation

In order to claim credit, participants must complete the following:

  • Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
  • Complete the Pre-Activity Questions.
  • Read or review the activity content.
  • Complete the Post-Activity Test Questions and Evaluation.
  • Learners who receive a grade of 66% or better on the Post-Activity Test Questions and complete the Evaluation will receive appropriate credit as indicated (CME, CNE, and/or CPE credit).
    CPE credit will be posted to the learner's CPE Monitor profile within 60 days of completion.
    CME and CNE credit will be issued appropriate certificate of completion.
    Others may request a "certificate of completion".
  • Learners should claim only the credit commensurate with the extent of their participation in the activity.

Statement of Commercial Support

This activity has been supported by an independent educational grant from AstraZeneca Pharmaceuticals.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and AstraZeneca Pharmaceuticals do not recommend the use of any agent outside of the labeled indications.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

For all CME/CE inquiries or special needs, please contact admin@academiccme.com or 610-687-3300.

Nephrology Presentations

1.00 CME / CNE / CPE
AcademicCME
Advances in the Management of Acute and Chronic Hyperkalemia

Advances in the Management of Acute and Chronic Hyperkalemia

Start

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: October 20, 2020
Expires: October 19, 2021
60 minutes to complete

Accredited By

Target Audience

Community and community hospital-based generalist and specialist physicians, nurses, and pharmacists who manage patients with hyperkalemia.

Learning Objectives

  • Assess for hyperkalemia risk in patients with underlying diseases like heart failure, diabetes, or chronic kidney disease
  • Understand and differentiate among therapies for temporizing, acute, and chronic therapy for hyperkalemia
  • Analyze the latest evidence-based data for hyperkalemia therapeutics to inform clinical decision making in an era of advanced treatment of heart failure, diabetes, and chronic kidney disease

Activity Description

Hyperkalemia and its important cardiometabolic comorbidities are increasingly common, while the most frequently used acute therapy to lower potassium levels for over five decades is now recognized as being associated with serious adverse effects. Over the last four years, clinical trial data has identified newer and safer therapeutic options. The goals of better potassium management include facilitation of guidelines-recommended therapy for heart failure and hypertension, and support of the patient with chronic renal disease. In this unique program, we will discuss new and improved options for managing hyperkalemia acutely and chronically. This information will impact the practices of emergency medicine physicians, hospitalists, internists, cardiologists, nephrologists, and other clinicians.

Statement of Educational Need

Health care team members need to understand the most recent clinical trial data regarding the treatment of management of patients with hyperkalemia.

Agenda

  • Understand the Hyperkalemia Risk in Patients With Heart failure, Diabetes, or Chronic Kidney Disease
  • Acute and Temporizing Management of Hyperkalemia
  • Data Analysis and Interpretation: Applicability to Practice of Newer Potassium Binders

Faculty

Charles V. Pollack Jr., MA, MD, FACEP, FAHA, FACC, FESC
Clinician-Scientist
Department of Emergency Medicine
University of Mississippi School of Medicine
Jackson, Mississippi


Javed Butler, MD, MPH, MBA
Chairman and Professor
Department of Medicine
University of Mississippi Medical Center
Jackson, Mississippi


Disclosures of Conflict of Interest

It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:

Charles V. Pollack, Jr., MA, MD, FACEP, FAHA, FACC, FESC (Course Chair)
Relationship Identified With:
Grant/Research Support: AstraZeneca Pharmaceuticals; Boehringer-Ingelheim Pharmaceuticals; CSL Behring.

Javed Butler, MD, MPH, MBA
Relationship Identified With:
Consultant/Advisor: Amgen Inc.; Array; AstraZeneca Pharmaceuticals; Bayer AG; Boehringer Ingelheim; Bristol-Myers Squibb Company; CVRX Inc.; G3 Pharmaceuticals; Innolife; Janssen Scientific Affairs LLC.; Luitpold Pharmaceuticals, Inc.; Merck & Co.; Medtronics; Novartis Pharmaceuticals Corporation; Relypsa Inc.

Accreditation Statement

In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. This activity was planned by and for the healthcare team.

Designation of Credit

AcademicCME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™.

AcademicCME designates this enduring material for a maximum of 1.0 CNE Contact Hour (Provider Number P0491).

AcademicCME designates this continuing education activity for 1.0 CPE Contact Hour (0.10 CEU) of continuing pharmacy education credit (UAN #: JA4008190-0000-20-007-L04-P).

Participants should claim only the credit commensurate with the extent of their participation in the activity.

Method of Participation

In order to claim credit, participants must complete the following:

  • Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
  • Complete the Pre-Activity Questions.
  • Read or review the activity content.
  • Complete the Post-Activity Test Questions and Evaluation.
  • Learners who receive a grade of 66% or better on the Post-Activity Test Questions and complete the Evaluation will receive appropriate credit as indicated (CME, CNE, and/or CPE credit).
    CPE credit will be posted to the learner's CPE Monitor profile within 60 days of completion.
    CME and CNE credit will be issued appropriate certificate of completion.
    Others may request a "certificate of completion".
  • Learners should claim only the credit commensurate with the extent of their participation in the activity.

Statement of Commercial Support

This activity has been supported by an independent educational grant from AstraZeneca Pharmaceuticals.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and AstraZeneca Pharmaceuticals do not recommend the use of any agent outside of the labeled indications.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

For all CME/CE inquiries or special needs, please contact admin@academiccme.com or 610-687-3300.

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: October 20, 2020
Expires: October 19, 2021
60 minutes to complete

Accredited By

Target Audience

Community and community hospital-based generalist and specialist physicians, nurses, and pharmacists who manage patients with hyperkalemia.

Learning Objectives

  • Assess for hyperkalemia risk in patients with underlying diseases like heart failure, diabetes, or chronic kidney disease
  • Understand and differentiate among therapies for temporizing, acute, and chronic therapy for hyperkalemia
  • Analyze the latest evidence-based data for hyperkalemia therapeutics to inform clinical decision making in an era of advanced treatment of heart failure, diabetes, and chronic kidney disease

Activity Description

Hyperkalemia and its important cardiometabolic comorbidities are increasingly common, while the most frequently used acute therapy to lower potassium levels for over five decades is now recognized as being associated with serious adverse effects. Over the last four years, clinical trial data has identified newer and safer therapeutic options. The goals of better potassium management include facilitation of guidelines-recommended therapy for heart failure and hypertension, and support of the patient with chronic renal disease. In this unique program, we will discuss new and improved options for managing hyperkalemia acutely and chronically. This information will impact the practices of emergency medicine physicians, hospitalists, internists, cardiologists, nephrologists, and other clinicians.

Statement of Educational Need

Health care team members need to understand the most recent clinical trial data regarding the treatment of management of patients with hyperkalemia.

Agenda

  • Understand the Hyperkalemia Risk in Patients With Heart failure, Diabetes, or Chronic Kidney Disease
  • Acute and Temporizing Management of Hyperkalemia
  • Data Analysis and Interpretation: Applicability to Practice of Newer Potassium Binders

Faculty

Charles V. Pollack Jr., MA, MD, FACEP, FAHA, FACC, FESC
Clinician-Scientist
Department of Emergency Medicine
University of Mississippi School of Medicine
Jackson, Mississippi


Javed Butler, MD, MPH, MBA
Chairman and Professor
Department of Medicine
University of Mississippi Medical Center
Jackson, Mississippi


Disclosures of Conflict of Interest

It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:

Charles V. Pollack, Jr., MA, MD, FACEP, FAHA, FACC, FESC (Course Chair)
Relationship Identified With:
Grant/Research Support: AstraZeneca Pharmaceuticals; Boehringer-Ingelheim Pharmaceuticals; CSL Behring.

Javed Butler, MD, MPH, MBA
Relationship Identified With:
Consultant/Advisor: Amgen Inc.; Array; AstraZeneca Pharmaceuticals; Bayer AG; Boehringer Ingelheim; Bristol-Myers Squibb Company; CVRX Inc.; G3 Pharmaceuticals; Innolife; Janssen Scientific Affairs LLC.; Luitpold Pharmaceuticals, Inc.; Merck & Co.; Medtronics; Novartis Pharmaceuticals Corporation; Relypsa Inc.

Accreditation Statement

In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. This activity was planned by and for the healthcare team.

Designation of Credit

AcademicCME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™.

AcademicCME designates this enduring material for a maximum of 1.0 CNE Contact Hour (Provider Number P0491).

AcademicCME designates this continuing education activity for 1.0 CPE Contact Hour (0.10 CEU) of continuing pharmacy education credit (UAN #: JA4008190-0000-20-007-L04-P).

Participants should claim only the credit commensurate with the extent of their participation in the activity.

Method of Participation

In order to claim credit, participants must complete the following:

  • Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
  • Complete the Pre-Activity Questions.
  • Read or review the activity content.
  • Complete the Post-Activity Test Questions and Evaluation.
  • Learners who receive a grade of 66% or better on the Post-Activity Test Questions and complete the Evaluation will receive appropriate credit as indicated (CME, CNE, and/or CPE credit).
    CPE credit will be posted to the learner's CPE Monitor profile within 60 days of completion.
    CME and CNE credit will be issued appropriate certificate of completion.
    Others may request a "certificate of completion".
  • Learners should claim only the credit commensurate with the extent of their participation in the activity.

Statement of Commercial Support

This activity has been supported by an independent educational grant from AstraZeneca Pharmaceuticals.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and AstraZeneca Pharmaceuticals do not recommend the use of any agent outside of the labeled indications.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

For all CME/CE inquiries or special needs, please contact admin@academiccme.com or 610-687-3300.

0.50 CME
University of Florida College of Medicine
The Clinical Significance of Imaging in the Management of ADPKD

The Clinical Significance of Imaging in the Management of ADPKD

Start

Activity Details

Free CME
0.5 AMA PRA Category 1 Credits
Released: May 27, 2020
Expires: May 26, 2021
30 minutes to complete

Target Audience

This activity has been designed to meet the educational needs of radiologists and other health care professionals involved in the diagnosis, treatment and management of patients with autosomal dominant polycystic kidney disease (ADPKD).

Overview

This Expert Exchange webcast is designed to help clinicians better understand the importance of radiologic imaging in the clinical management of patients affected by ADPKD.

Educational Objectives

Upon completion of this activity, participants will be better able to do the following:

  • Recognize the significance of total kidney volume (TKV) in ADPKD
  • Summarize the methods for assessing TKV
  • Recognize atypical vs. typical presentations of PKD
  • Summarize clinical decision-making steps regarding treatment decisions

Faculty

Bohyun Kim, MD, PhD
Chief, GU Section
Professor of Radiology
Mayo Clinic
Rochester, MN


Anjay Rastogi, MD, PhD
Director, PKD Program and CORE Kidney Program
Professor and Clinical Chief, Nephrology
UCLA Geffen School of Medicine
Los Angeles, CA


Financial Support

This activity has been supported by an independent educational grant from Otsuka America Pharmaceutical, Inc.

Providers

Jointly provided by the University of Florida College of Medicine and Novus Medical Education.

Joint Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Florida College of Medicine and Novus Medical Education. The University of Florida College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Physician Continuing Medical Education

The University of Florida College of Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest

The University of Florida College of Medicine requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to UF COM policy. UF COM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Faculty
Dr. Kim reports no relevant financial relationships to disclose.
Dr. Rastogi reports the following relevant financial relationships:

  • Speakers Bureau/Advisory Board - Genzyme/Sanofi, Otsuka
  • Research Support - Kadmon, Reata Pharmaceuticals, Sanofi

Planners and Managers
The UF COM and Novus Medical Education planners and managers have nothing to disclose.

Method of Participation

There are no fees for participating and receiving CME credit for this activity. To claim credit, participants must complete the following:

  • Read the educational objectives, accreditation information and faculty disclosures at the beginning of this activity.
  • Complete the pre-test.
  • View the webcast.
  • Complete the post-test and evaluation.
  • Physicians who receive a grade of 80% or better on the post-test and complete the evaluation will receive a CME certificate.
  • All other participants who receive a grade of 80% or better on the post-test and complete the evaluation will receive a Certificate of Participation.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

CME Provider

The University of Florida College of Medicine can be contacted at cme-mail@ufl.edu or 352.733.0064.

Activity Details

Free CME
0.5 AMA PRA Category 1 Credits
Released: May 27, 2020
Expires: May 26, 2021
30 minutes to complete

Target Audience

This activity has been designed to meet the educational needs of radiologists and other health care professionals involved in the diagnosis, treatment and management of patients with autosomal dominant polycystic kidney disease (ADPKD).

Overview

This Expert Exchange webcast is designed to help clinicians better understand the importance of radiologic imaging in the clinical management of patients affected by ADPKD.

Educational Objectives

Upon completion of this activity, participants will be better able to do the following:

  • Recognize the significance of total kidney volume (TKV) in ADPKD
  • Summarize the methods for assessing TKV
  • Recognize atypical vs. typical presentations of PKD
  • Summarize clinical decision-making steps regarding treatment decisions

Faculty

Bohyun Kim, MD, PhD
Chief, GU Section
Professor of Radiology
Mayo Clinic
Rochester, MN


Anjay Rastogi, MD, PhD
Director, PKD Program and CORE Kidney Program
Professor and Clinical Chief, Nephrology
UCLA Geffen School of Medicine
Los Angeles, CA


Financial Support

This activity has been supported by an independent educational grant from Otsuka America Pharmaceutical, Inc.

Providers

Jointly provided by the University of Florida College of Medicine and Novus Medical Education.

Joint Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Florida College of Medicine and Novus Medical Education. The University of Florida College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Physician Continuing Medical Education

The University of Florida College of Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest

The University of Florida College of Medicine requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to UF COM policy. UF COM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Faculty
Dr. Kim reports no relevant financial relationships to disclose.
Dr. Rastogi reports the following relevant financial relationships:

  • Speakers Bureau/Advisory Board - Genzyme/Sanofi, Otsuka
  • Research Support - Kadmon, Reata Pharmaceuticals, Sanofi

Planners and Managers
The UF COM and Novus Medical Education planners and managers have nothing to disclose.

Method of Participation

There are no fees for participating and receiving CME credit for this activity. To claim credit, participants must complete the following:

  • Read the educational objectives, accreditation information and faculty disclosures at the beginning of this activity.
  • Complete the pre-test.
  • View the webcast.
  • Complete the post-test and evaluation.
  • Physicians who receive a grade of 80% or better on the post-test and complete the evaluation will receive a CME certificate.
  • All other participants who receive a grade of 80% or better on the post-test and complete the evaluation will receive a Certificate of Participation.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

CME Provider

The University of Florida College of Medicine can be contacted at cme-mail@ufl.edu or 352.733.0064.

0.25 CME
Global Education Group
The Radiologist's Role in the ADPKD Care Continuum: From Diagnosis to Monitoring Disease Progression

The Radiologist's Role in the ADPKD Care Continuum: From Diagnosis to Monitoring Disease Progression

Start

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: November 27, 2019
Expires: November 26, 2020
15 minutes to complete

Jointly Provided by


In Collaboration with


Target Audience

Diagnostic and interventional radiologists

Learning Objectives

  • Recognize the radiographic features of ADPKD and how they differ from other renal conditions
  • Discuss optimal strategies for use of MRI in evaluating potential candidates for initiating ADPKD therapy and for monitoring the course of disease progression over time

Activity Description

A concise, 15-minute Video Curbside Consult activity will provide a relaxed, casual atmosphere for two expert faculty – one radiologist and one nephrologist – to discuss effective partnering for improving care for patients with ADPKD. Faculty will be filmed using comfortable and inviting staging to match the collegial style of their discussion. The activity will use video interspersed with interactive questions to engage learners and measure their levels of knowledge and understanding at multiple points. Content will focus on the role of the radiologist in the ADPKD care continuum, including initial diagnosis and ongoing monitoring for disease progression.

Statement of Educational Need

Radiologists are challenged to conduct appropriate imaging studies of patients with renal disease, including ADPKD. Radiologists are underutilizing MRI for monitoring progression of ADPKD and are unaware of the most accurate methods for conducting such imaging studies.

Agenda

  • Brief introduction of ADPKD
  • Need for nephrologist-radiologist partnership
  • Role of radiologists in the ADPKD care continuum
    • ADPKD diagnosis
      • When to suspect ADPKD
      • Establishing an ADPKD diagnosis
      • Guidelines for different age cohorts
      • Use of ultrasound versus other imaging options
    • Monitoring and measurement of ADPKD disease progression
      • When and how often is imaging needed?
      • Use of MRI versus other imaging options (abdominal ultrasound and computed tomography)
  • Recommendations for ongoing radiologist-nephrologist communication
  • Summary of key teaching points

Faculty

Gary Israel, MD
Yale University School of Medicine
New Haven, CT
  • Disclosure:
    • Nothing to disclose


Neera Dahl, MD
Yale University School of Medicine
New Haven, CT
  • Disclosure:
    • Consultant/Independent Contractor: Otsuka America Pharmaceutical, Inc.
    • Advisory Board: Otsuka America Pharmaceutical, Inc.


Planners/Managers:
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Lindsay Borvansky    Nothing to disclose
Andrea Funk    Nothing to disclose
Liddy Knight    Nothing to disclose
Ashley Cann    Nothing to disclose
Ron Schaumburg    Nothing to disclose
Nicola Sirdevan    Nothing to disclose

Conflict of Interest Policy/Disclosure Statement

Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Global Academy for Medical Education. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

Global Education Group designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

In order to receive credit for this activity, participants must complete the activity. Participants must also score at least 70% on the posttest and complete the activity evaluations.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Statement of Commercial Support

This activity is supported by an independent educational grant from Otsuka America Pharmaceutical, Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and Global Academy for Medical Education do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari.

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: November 27, 2019
Expires: November 26, 2020
15 minutes to complete

Jointly Provided by


In Collaboration with


Target Audience

Diagnostic and interventional radiologists

Learning Objectives

  • Recognize the radiographic features of ADPKD and how they differ from other renal conditions
  • Discuss optimal strategies for use of MRI in evaluating potential candidates for initiating ADPKD therapy and for monitoring the course of disease progression over time

Activity Description

A concise, 15-minute Video Curbside Consult activity will provide a relaxed, casual atmosphere for two expert faculty – one radiologist and one nephrologist – to discuss effective partnering for improving care for patients with ADPKD. Faculty will be filmed using comfortable and inviting staging to match the collegial style of their discussion. The activity will use video interspersed with interactive questions to engage learners and measure their levels of knowledge and understanding at multiple points. Content will focus on the role of the radiologist in the ADPKD care continuum, including initial diagnosis and ongoing monitoring for disease progression.

Statement of Educational Need

Radiologists are challenged to conduct appropriate imaging studies of patients with renal disease, including ADPKD. Radiologists are underutilizing MRI for monitoring progression of ADPKD and are unaware of the most accurate methods for conducting such imaging studies.

Agenda

  • Brief introduction of ADPKD
  • Need for nephrologist-radiologist partnership
  • Role of radiologists in the ADPKD care continuum
    • ADPKD diagnosis
      • When to suspect ADPKD
      • Establishing an ADPKD diagnosis
      • Guidelines for different age cohorts
      • Use of ultrasound versus other imaging options
    • Monitoring and measurement of ADPKD disease progression
      • When and how often is imaging needed?
      • Use of MRI versus other imaging options (abdominal ultrasound and computed tomography)
  • Recommendations for ongoing radiologist-nephrologist communication
  • Summary of key teaching points

Faculty

Gary Israel, MD
Yale University School of Medicine
New Haven, CT
  • Disclosure:
    • Nothing to disclose


Neera Dahl, MD
Yale University School of Medicine
New Haven, CT
  • Disclosure:
    • Consultant/Independent Contractor: Otsuka America Pharmaceutical, Inc.
    • Advisory Board: Otsuka America Pharmaceutical, Inc.


Planners/Managers:
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Lindsay Borvansky    Nothing to disclose
Andrea Funk    Nothing to disclose
Liddy Knight    Nothing to disclose
Ashley Cann    Nothing to disclose
Ron Schaumburg    Nothing to disclose
Nicola Sirdevan    Nothing to disclose

Conflict of Interest Policy/Disclosure Statement

Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Global Academy for Medical Education. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

Global Education Group designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

In order to receive credit for this activity, participants must complete the activity. Participants must also score at least 70% on the posttest and complete the activity evaluations.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Statement of Commercial Support

This activity is supported by an independent educational grant from Otsuka America Pharmaceutical, Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and Global Academy for Medical Education do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari.